| 5 min read
With gene therapy now a clinical reality, innovators are designing delivery systems that can sustain lifelong correction, handle complex genes, and make treatments accessible to more patients.
| 4 min read
Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
| 4 min read
GPCRs drive a huge portion of today’s drug market, but producing them in a functional form remains a major bottleneck for discovery and structural studies.News
| 3 min read
Moved by magnets or ultrasound waves, these tiny robots make delivering drugs more accurate and effective.
| 3 min read
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
| 5 min read
Efferent Labs’ implantable biosensor provides real-time, continuous insight into how drugs interact with living systems.
| 4 min read
Vaccination guidances, promising trial outcomes, funding bills and more led the news this week.
| 3 min read
Data presented at the American Heart Association’s International Stroke Conference highlight a potential shift in stroke prevention.
| 6 min read
With multiple trials underway and billions in investment, psychedelic therapies are moving from experimental research toward mainstream mental health care.
| 5 min read
Automation, digital manufacturing, and regulatory reform are reshaping how the UK competes in cell and gene therapy as the field moves toward routine delivery.
| 4 min read
These late-stage therapies span obesity, diabetes, hypertension, and allergy care, offering new mechanisms and delivery formats that could reshape patient treatment.
| 3 min read
Multi-omics analysis reveals a nine-gene signature linked to treatment failure in aggressive tumor behavior.
